6241. Breath of Life: Heart Disease Link to Developmental Hypoxia.
Heart disease remains one of the greatest killers. In addition to genetics and traditional lifestyle risk factors, we now understand that adverse conditions during pregnancy can also increase susceptibility to cardiovascular disease in the offspring. Therefore, the mechanisms by which this occurs and possible preventative therapies are of significant contemporary interest to the cardiovascular community. A common suboptimal pregnancy condition is a sustained reduction in fetal oxygenation. Chronic fetal hypoxia results from any pregnancy with increased placental vascular resistance, such as in preeclampsia, placental infection, or maternal obesity. Chronic fetal hypoxia may also arise during pregnancy at high altitude or because of maternal respiratory disease. This article reviews the short- and long-term effects of hypoxia on the fetal cardiovascular system, and the importance of chronic fetal hypoxia in triggering a developmental origin of future heart disease in the adult progeny. The work summarizes evidence derived from human studies as well as from rodent, avian, and ovine models. There is a focus on the discovery of the molecular link between prenatal hypoxia, oxidative stress, and increased cardiovascular risk in adult offspring. Discussion of mitochondria-targeted antioxidant therapy offers potential targets for clinical intervention in human pregnancy complicated by chronic fetal hypoxia.
6242. Cardiovascular Progerin Suppression and Lamin A Restoration Rescue Hutchinson-Gilford Progeria Syndrome.
作者: Amanda Sánchez-López.;Carla Espinós-Estévez.;Cristina González-Gómez.;Pilar Gonzalo.;María J Andrés-Manzano.;Víctor Fanjul.;Raquel Riquelme-Borja.;Magda R Hamczyk.;Álvaro Macías.;Lara Del Campo.;Emilio Camafeita.;Jesús Vázquez.;Anna Barkaway.;Loïc Rolas.;Sussan Nourshargh.;Beatriz Dorado.;Ignacio Benedicto.;Vicente Andrés.
来源: Circulation. 2021年144卷22期1777-1794页
Hutchinson-Gilford progeria syndrome (HGPS) is a rare disorder characterized by premature aging and death mainly because of myocardial infarction, stroke, or heart failure. The disease is provoked by progerin, a variant of lamin A expressed in most differentiated cells. Patients look healthy at birth, and symptoms typically emerge in the first or second year of life. Assessing the reversibility of progerin-induced damage and the relative contribution of specific cell types is critical to determining the potential benefits of late treatment and to developing new therapies.
6243. CARMN Is an Evolutionarily Conserved Smooth Muscle Cell-Specific LncRNA That Maintains Contractile Phenotype by Binding Myocardin.
作者: Kunzhe Dong.;Jian Shen.;Xiangqin He.;Guoqing Hu.;Liang Wang.;Islam Osman.;Kristopher M Bunting.;Rachael Dixon-Melvin.;Zeqi Zheng.;Hongbo Xin.;Meixiang Xiang.;Almira Vazdarjanova.;David J R Fulton.;Jiliang Zhou.
来源: Circulation. 2021年144卷23期1856-1875页
Vascular homeostasis is maintained by the differentiated phenotype of vascular smooth muscle cells (VSMCs). The landscape of protein coding genes comprising the transcriptome of differentiated VSMCs has been intensively investigated but many gaps remain including the emerging roles of noncoding genes.
6244. Brugada Syndrome: New Insights From Cardiac Magnetic Resonance and Electroanatomical Imaging.
作者: Carlo Pappone.;Vincenzo Santinelli.;Valerio Mecarocci.;Lara Tondi.;Giuseppe Ciconte.;Francesco Manguso.;Francesco Sturla.;Gabriele Vicedomini.;Emanuele Micaglio.;Luigi Anastasia.;Silvia Pica.;Antonia Camporeale.;Massimo Lombardi.
来源: Circ Arrhythm Electrophysiol. 2021年14卷11期e010004页
Brugada syndrome (BrS) is considered a purely electrical disease with variable electrical substrates. Variable rates of mechanical abnormalities have been also reported. Whether exists a link between electrical and mechanical abnormalities has never been previously explored. This investigational physiopathological study aimed to determine the relationship between the substrate size/location, as exposed by ajmaline provocation, and the severity of mechanical abnormalities, as assessed by cardiac magnetic resonance in patients with BrS.
6245. Catheter Ablation for Atrial Fibrillation in Hyperthyroid Patients.
作者: Philipp Krisai.;Ghassen Cheniti.;Tsukasa Kamakura.;Takamitsu Takagi.;Clémentine André.;F Daniel Ramirez.;Yosuke Nakatani.;Takashi Nakashima.;Romain Tixier.;Rémi Chauvel.;Xavier Pillois.;Josselin Duchateau.;Thomas Pambrun.;Nicolas Derval.;Frédéric Sacher.;Mélèze Hocini.;Michel Haïssaguerre.;Pierre Jaïs.
来源: Circ Arrhythm Electrophysiol. 2021年14卷11期e010200页 6246. Strategies for Promotion of a Healthy Lifestyle in Clinical Settings: Pillars of Ideal Cardiovascular Health: A Science Advisory From the American Heart Association.
作者: Penny M Kris-Etherton.;Kristina S Petersen.;Jean-Pierre Després.;Cheryl A M Anderson.;Prakash Deedwania.;Karen L Furie.;Scott Lear.;Alice H Lichtenstein.;Felipe Lobelo.;Pamela B Morris.;Frank M Sacks.;Jun Ma.
来源: Circulation. 2021年144卷24期e495-e514页
Engagement in healthy lifestyle behaviors is suboptimal. The vast majority of the US population does not meet current recommendations. A healthy lifestyle is defined by consuming a healthy dietary pattern, engaging in regular physical activity, avoiding exposure to tobacco products, habitually attaining adequate amounts of sleep, and managing stress levels. For all these health behaviors there are well-established guidelines; however, promotion in clinical settings can be challenging. It is critical to overcome these challenges because greater promotion of heathy lifestyle practices in clinical settings effectively motivates and initiates patient behavior change. The 5A Model (assess, advise, agree, assist, and arrange) was developed to provide a framework for clinical counseling with requisite attention to the demands of clinical settings. In this science advisory, we present strategies, based on the 5A Model, that clinicians and other health care professionals can use for efficient lifestyle-related behavior change counseling in patients at all levels of cardiovascular disease risk at every visit. In addition, we discuss the underlying role of psychological health and well-being in lifestyle-related behavior change counseling, and how clinicians can leverage health technologies when providing brief patient-centered counseling. Greater attention to healthy lifestyle behaviors during routine clinician visits will contribute to promoting cardiovascular health.
6247. Changing Demographics, Temporal Trends in Waitlist, and Posttransplant Outcomes After Heart Transplantation in the United States: Analysis of the UNOS Database 1991-2019.
作者: Emmanuel Akintoye.;Paulino Alvarez.;Doosup Shin.;Alexander Egbe.;Anthony Panos.;Frank Sellke.;Alexandros Briasoulis.
来源: Circ Heart Fail. 2021年14卷11期e008764页
We sought to investigate temporal trends in patient characteristics, waitlist, and posttransplant outcomes after heart transplantation in the United States.
6248. FGF-23 (Fibroblast Growth Factor-23) and Cardiorenal Interactions.
作者: Juan B Ivey-Miranda.;Brendan Stewart.;Zachary L Cox.;Wendy McCallum.;Christopher Maulion.;Olyvia Gleason.;Grace Meegan.;Jonathan G Amatruda.;Julieta Moreno-Villagomez.;Devin Mahoney.;Jeffrey M Turner.;F Perry Wilson.;Michelle M Estrella.;Michael G Shlipak.;Veena S Rao.;Jeffrey M Testani.
来源: Circ Heart Fail. 2021年14卷11期e008385页
Animal models implicate FGF-23 (fibroblast growth factor-23) as a direct contributor to adverse cardiorenal interactions such as sodium avidity, diuretic resistance, and neurohormonal activation, but this has not been conclusively demonstrated in humans. Therefore, we aimed to evaluate whether FGF-23 is associated with parameters of cardiorenal dysfunction in humans with heart failure, independent of confounding factors.
6249. Special Considerations for Healthy Lifestyle Promotion Across the Life Span in Clinical Settings: A Science Advisory From the American Heart Association.
作者: Penny M Kris-Etherton.;Kristina S Petersen.;Jean-Pierre Després.;Lynne Braun.;Sarah D de Ferranti.;Karen L Furie.;Scott A Lear.;Felipe Lobelo.;Pamela B Morris.;Frank M Sacks.
来源: Circulation. 2021年144卷24期e515-e532页
At a population level, engagement in healthy lifestyle behaviors is suboptimal in the United States. Moreover, marked disparities exist in healthy lifestyle behaviors and cardiovascular risk factors as a result of social determinants of health. In addition, there are specific challenges to engaging in healthy lifestyle behaviors related to age, developmental stage, or major life circumstances. Key components of a healthy lifestyle are consuming a healthy dietary pattern, engaging in regular physical activity, avoiding use of tobacco products, habitually attaining adequate sleep, and managing stress. For these health behaviors, there are guidelines and recommendations; however, promotion in clinical settings can be challenging, particularly in certain population groups. These challenges must be overcome to facilitate greater promotion of healthy lifestyle practices in clinical settings. The 5A Model (assess, advise, agree, assist, and arrange) was developed to provide a framework for clinical counseling with consideration for the demands of clinical settings. In this science advisory, we summarize specific considerations for lifestyle-related behavior change counseling using the 5A Model for patients across the life span. In all life stages, social determinants of health and unmet social-related health needs, as well as overweight and obesity, are associated with increased risk of cardiovascular disease, and there is the potential to modify this risk with lifestyle-related behavior changes. In addition, specific considerations for lifestyle-related behavior change counseling in life stages in which lifestyle behaviors significantly affect cardiovascular disease risk are outlined. Greater attention to healthy lifestyle behaviors during every clinician visit will contribute to improved cardiovascular health.
6251. Comparison Between Septal Pacing With the Catheter Delivery System and Apical Pacing With the Stylet Delivery System for Ventricular Lead Placement: A Randomized Controlled Trial.
作者: Kenichiro Yamagata.;Kohei Ishibashi.;Akinori Wakamiya.;Keiko Shimamoto.;Nobuhiko Ueda.;Tsukasa Kamakura.;Mitsuru Wada.;Yuko Inoue.;Koji Miyamoto.;Takashi Noda.;Satoshi Nagase.;Takeshi Aiba.;Kengo Kusano.
来源: Circ Arrhythm Electrophysiol. 2021年14卷11期e010362页 6253. Impact of Periprocedural Myocardial Injury and Infarction Definitions on Long-Term Mortality After Chronic Total Occlusion Percutaneous Coronary Intervention.
作者: Lei Song.;Yang Wang.;Changdong Guan.;Tongqiang Zou.;Zhongwei Sun.;Lihua Xie.;Rui Zhang.;Kefei Dou.;Weixian Yang.;Yongjian Wu.;Shubin Qiao.;Bo Xu.
来源: Circ Cardiovasc Interv. 2021年14卷11期e010923页
The prognostic implications of biomarker elevation following percutaneous coronary intervention (PCI) of chronic total occlusion (CTO) lesions remain controversial. This study assessed the association of periprocedural myocardial injury and clinically relevant definition of periprocedural myocardial infarction with subsequent outcomes after CTO-PCI.
6254. Balloon-Augmented Leaflet Modification With Bioprosthetic or Native Aortic Scallop Intentional Laceration to Prevent Iatrogenic Coronary Artery Obstruction and Laceration of the Anterior Mitral Leaflet to Prevent Outflow Obstruction: Benchtop Validation and First In-Man Experience.
作者: Emily Perdoncin.;Christopher G Bruce.;Vasilis C Babaliaros.;Dursun Korel Yildirim.;Jeremiah P Depta.;James M McCabe.;Patrick T Gleason.;Joe Xie.;Kendra J Grubb.;Gaetano Paone.;Keshav Kohli.;Norihiko Kamioka.;Jaffar M Khan.;Toby Rogers.;Robert J Lederman.;Adam B Greenbaum.
来源: Circ Cardiovasc Interv. 2021年14卷11期e011028页
Bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction (BASILICA) and laceration of the anterior mitral leaflet to prevent outflow obstruction (LAMPOON) reduce the risk of coronary and left ventricular outflow obstruction obstruction during transcatheter aortic valve replacement and transcatheter mitral valve replacement. Despite successful laceration, BASILICA or LAMPOON may fail to prevent obstruction caused by inadequate leaflet splay in patients having challenging anatomy such as very small valve-to-coronary distance, diffusely calcified, rigid leaflets, or undergoing transcatheter aortic valve replacement inside existing transcatheter aortic valve replacement. We describe a novel technique of balloon-augmented (BA) leaflet laceration to enhance leaflet splay.
6255. Prognostic Impact of Pancoronary Quantitative Flow Ratio Assessment in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes.
作者: Aslihan Erbay.;Lisa Penzel.;Youssef S Abdelwahed.;Jens Klotsche.;Andrea Heuberger.;Anne-Sophie Schatz.;Julia Steiner.;Arash Haghikia.;David Sinning.;Georg M Fröhlich.;Ulf Landmesser.;Barbara E Stähli.;David M Leistner.
来源: Circ Cardiovasc Interv. 2021年14卷12期e010698页
Quantitative flow ratio (QFR) has been introduced as a novel angiography-based modality for fast hemodynamic assessment of coronary artery lesions and validated against fractional flow reserve. This study sought to define the prognostic role of pancoronary QFR assessment in patients with acute coronary syndrome (ACS) including postinterventional culprit and nonculprit vessels.
6256. Association Between Stent Implantation and Progression of Nontarget Lesions in a Rabbit Model of Atherosclerosis.
作者: Jing Ma.;Xiaoling Liu.;Lei Qiao.;Linlin Meng.;Xingli Xu.;Fei Xue.;Cheng Cheng.;Ziqi Han.;Yue Lu.;Wencheng Zhang.;Peili Bu.;Meng Zhang.;Guipeng An.;Huixia Lu.;Mei Ni.;Cheng Zhang.;Yun Zhang.
来源: Circ Cardiovasc Interv. 2021年14卷11期e010764页
Progression of nontarget lesions (NTLs) after percutaneous coronary intervention (PCI) has been reported. However, it remains unknown whether progression of NTLs was causally related to stenting. This study was undertaken to test the hypothesis that stent implantation triggers acute phase response and systemic inflammation which may be associated with progression of NTLs.
6257. Joint Modeling of Longitudinal Markers and Time-to-Event Outcomes: An Application and Tutorial in Patients After Surgical Repair of Transposition of the Great Arteries.
作者: Sara J Baart.;Roel L F van der Palen.;Hein Putter.;Roula Tsonaka.;Nico A Blom.;Dimitris Rizopoulos.;Nan van Geloven.
来源: Circ Cardiovasc Qual Outcomes. 2021年14卷11期e007593页
Most patients with congenital heart disease survive into adulthood; however, residual abnormalities remain and management of the patients is life-long and personalized. Patients with surgical repair of transposition of the great arteries, for example, face the risk to develop neoaortic valve regurgitation. Cardiologists update the prognosis of the patient intuitively with updated information of the cardiovascular status of the patient, for instance from echocardiographic imaging.
6258. Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction.
作者: Masatoshi Minamisawa.;Brian Claggett.;Kota Suzuki.;Sheila M Hegde.;Amil M Shah.;Akshay S Desai.;Eldrin F Lewis.;Sanjiv J Shah.;Nancy K Sweitzer.;James C Fang.;Inder S Anand.;Eileen O'Meara.;Jean-Lucien Rouleau.;Bertram Pitt.;Marc A Pfeffer.;Scott D Solomon.;Orly Vardeny.
来源: Circ Heart Fail. 2021年14卷11期e008293页
Polypharmacy is associated with a poor prognosis in the elderly, however, information on the association of polypharmacy with cardiovascular outcomes in heart failure with preserved ejection fraction is sparse. This study sought to investigate the relationship between polypharmacy and adverse cardiovascular events in patients with heart failure with preserved ejection fraction.
6259. Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry.
作者: Muhammad Shahzeb Khan.;Stephen J Greene.;Anne S Hellkamp.;Adam D DeVore.;Xian Shen.;Nancy M Albert.;J Herbert Patterson.;John A Spertus.;Laine E Thomas.;Fredonia B Williams.;Adrian F Hernandez.;Gregg C Fonarow.;Javed Butler.
来源: Circ Heart Fail. 2021年14卷11期e008351页
Diuretics are a mainstay therapy for the symptomatic treatment of heart failure. However, in contemporary US outpatient practice, the degree to which diuretic dosing changes over time and the associations with clinical outcomes and health care resource utilization are unknown.
6260. Altered Cardiac Energetics and Mitochondrial Dysfunction in Hypertrophic Cardiomyopathy.
作者: Sara Ranjbarvaziri.;Kristina B Kooiker.;Mathew Ellenberger.;Giovanni Fajardo.;Mingming Zhao.;Alison Schroer Vander Roest.;Rahel A Woldeyes.;Tiffany T Koyano.;Robyn Fong.;Ning Ma.;Lei Tian.;Gavin M Traber.;Frandics Chan.;John Perrino.;Sushma Reddy.;Wah Chiu.;Joseph C Wu.;Joseph Y Woo.;Kathleen M Ruppel.;James A Spudich.;Michael P Snyder.;Kévin Contrepois.;Daniel Bernstein.
来源: Circulation. 2021年144卷21期1714-1731页
Hypertrophic cardiomyopathy (HCM) is a complex disease partly explained by the effects of individual gene variants on sarcomeric protein biomechanics. At the cellular level, HCM mutations most commonly enhance force production, leading to higher energy demands. Despite significant advances in elucidating sarcomeric structure-function relationships, there is still much to be learned about the mechanisms that link altered cardiac energetics to HCM phenotypes. In this work, we test the hypothesis that changes in cardiac energetics represent a common pathophysiologic pathway in HCM.
|